AXINN

Axinn Successfully Represents Alvogen Before FTC

November 3, 2015

ATTORNEYS

Keeley, Michael

Lee, Kenina

PRACTICE AREAS

Antitrust

Axinn successfully represented Alvogen before the Federal Trade Commission in connection with Alvogen's approval to buy the divestiture products in the proposed Mylan/Perrigo transaction. Mylan's bid for Perrigo is valued at $25 billion, and Alvogen will acquire seven separate pharmaceutical products as a result of the FTC-mandated and approved divestiture. Alvogen was also approved to acquire the divestiture products in Pfizer/Hospira earlier this year. The FTC's Mylan press release can be found here.

The Axinn team based in Washington, DC consisted of partner Michael Keeley, assisted by associate Kenina Lee.

© 2024 AXINN, VELTROP & HARKRIDER LLP